Detail akcie Rallybio Rg online

Business Summary: Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Rallybio Corp revenues increased 6% to $636K. Net loss decreased 93% to $3.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects clinical-stage biotechnology segment loss decrease of 32% to $19.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$8.73 to -$0.57.